NDA 021434 · Upjohn
Xanax Xr
Alprazolam · Oral · Benzodiazepine
Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Jan 17, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
103
8 Phase 3, 7 recruiting
FAERS reports
207,039
146,112 serious, 33,619 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] . • The use of benzodiazepines, including alprazolam XR, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse...
What it is approved for
From the label in effect Feb 11, 2025.
Alprazolam XR is indicated for the treatment of panic disorder with or without agoraphobia, in adults. Alprazolam XR is a benzodiazepine indicated for the treatment of panic disorder with or without agoraphobia, in adults. ( 1 )
Mechanism: Alprazolam is a 1,4 benzodiazepine. Alprazolam exerts its effect for the treatment of panic disorder through binding to the benzodiazepine site of gamma‑aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- XANAX XR · ALPRAZOLAM 2MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- XANAX XR · ALPRAZOLAM 0.5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- XANAX XR · ALPRAZOLAM 3MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
- XANAX XR · ALPRAZOLAM 1MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Alprazolam" as an intervention, any sponsor and status, largest first.
- LUSZ Treatment Efficacy in Hospitalized COVID-19 PatientsPivotal-lookingStatus unknown
Lebanese UniversityAcademic, hospital or other
NCT05925140 · 1,000 participants (planned) · Start Mar 28, 2020 · Primary completion Dec 30, 2024
Drug: Lopinavir / Ritonavir; Remdesivir (RDV) and 1 more · For: COVID-19; Hospitalized COVID-19 Patients
Sites: Zghartā, Lebanon; Tripoli, Lebanon
- Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)Pivotal-lookingCompleted
McMaster UniversityAcademic, hospital or other
NCT03053869 · 480 participants · Start Apr 1, 2017 · Primary completion Sep 30, 2018
Drug: Benzodiazepine - limited use strategy; Benzodiazepine - Ad libitum strategy · For: Post-operative Delirium
Sites: Winnipeg, Canada; Hamilton, Canada
- Reassessment of Premedication in SurgeryPivotal-lookingCompleted
University Hospital, AngersGovernment (non-federal)
NCT01549691 · 455 participants (planned) · Start Mar 2012 · Primary completion Apr 2013
Drug: Zopiclone; Alprazolam and 1 more · For: Anxiety
Sites: Cesson, France; Reims, France; Angers, France · 8 sites in all
UCB PharmaUCB
NCT00266409 · 418 participants · Start Oct 2005 · Primary completion Jun 2006
Drug: Niravam; SSRI/SNRI · For: Generalized Anxiety Disorder; Panic Disorder
Sites: Milwaukee, Wisconsin
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Anxiety and Surgery Satisfaction for Cataract Patient With Different State AnxietyPivotal-lookingRecruiting
National Taiwan University HospitalAcademic, hospital or other
NCT06826417 · 400 participants (planned) · Start Jan 2, 2024 · Primary completion Sep 11, 2026
Drug: Xanax · For: Oral Anxiolytic; Phacoemulsification; Cataract Surgery and 2 more
Sites: Taipei, Taiwan
- A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresPivotal-lookingRecruiting
NCT05077904 · 350 participants (planned) · Start Dec 7, 2021 · Primary completion Mar 29, 2027
Drug: Staccato alprazolam · For: Stereotypical Prolonged Seizures
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 183 sites in all
- Effect of IE Glasses on MRI Patient OutcomesNot yet recruiting
Baptist Health South FloridaAcademic, hospital or other
NCT07660952 · 300 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2027
Drug: Standard of Care: Anesthesia; Standard of Care: Sedative · For: MRI-related Anxiety; MRI Completion Rate
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective13,789
- nausea13,196
- fatigue12,296
- drug abuse11,218
- anxiety10,409
- headache10,216
- pain10,043
- toxicity to various agents9,151
- diarrhoea9,101
- dyspnoea8,523
- dizziness8,095
- completed suicide7,665
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,043 |
| 2005 | 3,603 |
| 2006 | 3,463 |
| 2007 | 3,268 |
| 2008 | 4,048 |
| 2009 | 4,921 |
| 2010 | 7,823 |
| 2011 | 7,878 |
| 2012 | 9,792 |
| 2013 | 9,604 |
| 2014 | 10,368 |
| 2015 | 14,132 |
| 2016 | 14,600 |
| 2017 | 13,485 |
| 2018 | 14,883 |
| 2019 | 15,448 |
| 2020 | 14,606 |
| 2021 | 10,517 |
| 2022 | 9,670 |
| 2023 | 8,861 |
| 2024 | 8,543 |
| 2025 | 8,413 |
| 2026 | 6,063 |
Recalls
2 FDA enforcement reports for this application.
Mar 17, 2026 · Class II · Ongoing
Failed Dissolution Specifications
Apr 28, 2022 · Class II · Terminated
Failed Dissolution Specifications: low out-of-specification dissolution test results observed.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xanax XR (Alprazolam)
2024 spending
$222K
Beneficiaries
54
299 claims
Per beneficiary
$4,117
$11.62 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $316,484 |
| 2021 | $390,402 |
| 2022 | $348,234 |
| 2023 | $294,924 |
| 2024 | $222,336 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G, Meader N, Barbui C, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Efficacy and safety of pharmacological treatments in borderline personality disorder: A systematic review and network meta-analysis.
Gerolymos C, Garosi A, Boyer L, et al. · Mol Psychiatry 2026 · Systematic Review, Network Meta-Analysis
- Alprazolam for depression.
van Marwijk H, Allick G, Wegman F, et al. · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial.
Dunbar J, Walling DP, Hassman HA, et al. · J Psychopharmacol 2024 · Clinical Trial, Phase I, Randomized Controlled Trial
- Alprazolam for essential tremor.
Bruno E, Nicoletti A, Quattrocchi G, et al. · Cochrane Database Syst Rev 2015 · Systematic Review
- Mapping the Synchronization Effect of Gamma-Aminobutyric Acid Inhibition on the Cerebral Cortex Using Magnetic Resonance Imaging.
Blanco-Hinojo L, Pujol J, Macià D, et al. · Brain Connect 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Upjohn
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.